Our preliminary data indicate that bortezomib is an active agent in patients with heavily pretreated relapsed/refractory WM. Four cycles of this agent may be adequate to assess sensitivity in this disease. Further studies are needed to confirm our results and to evaluate combinations of bortezomib with other active agents.
David S. Siegel, Sundar Jagannath, Roman Hájek, Meletios A Dimopoulos, Sung‐Soo Yoon, Sagar Lonial, Jacob P. Laubach, Thorsten Graef, Dina Pietrangelo, Lisa Lupinacci, David Reiser, Kenneth C. Anderson
Discussion(0)
No comments yet. Be the first to comment.